Molecular analysis coupling of some amino-derivatives with WRN exonuclease using a theoretical model
DOI:
https://doi.org/10.14295/bjs.v4i8.754Keywords:
Cancer, HOMO, LUMO, 2fbt protein, WRN exonucleaseAbstract
Studies indicate that some types of cancer have been associated with Werner syndrome (WR), which is characterized by premature aging. Some WR inhibitors, such as camptothecin, HRO761, VVD-133214, and KWR05, have been used to treat this clinical pathology; however, the interaction of these drugs with some biomolecule related with WR is not clear. For this reason, in this study, the coupling of amino derivatives (compounds 1-25) with WRN exonuclease was determined using 2fbt protein, HOR761, NSC19630, NSC617145, and NCS drugs as theoretical tools in the DockingServer program. Besides, physicochemical parameters, such as HOMO (highest occupied molecular orbital), LUMO (lowest unoccupied molecular orbital), MR (molecular refractivity), and MV (molar volume), involved in the chemical structure of amino derivatives 1-25 were determined. The results showed differences in HOMO-LUMO, MR, and MV values for compounds 1-25. This data suggests that the reactivity of each compound depends on different functional groups involved in their chemical structure. Other data indicate that inhibition constant involved in the coupling of amino derivatives with 2fbt protein for compounds 3 (1.30), 6 (1.20), 7 (1.46), 8 (1.03), 14 (1.04), 15 (1.02), and 21 (2.57) was lower in comparison with the controls. These data indicate that these amino derivatives have higher affinity for the 2fbt protein surface, which may translate as changes in the biological activity of the WRN exonuclease and induce changes in cancer cell growth.
References
Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W., & Vazquez, F. (2025). The present and future of the Cancer Dependency Map. Nature Reviews Cancer, 25(1), 59-73.
Bakchi, B., Krishna, A., Sreecharan, E., Ganesh, V., Niharika, M., Maharshi, S., & Shaik, A. (2022). An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: a medicinal chemist's perspective. Journal of Molecular Structure, 1259, 132712. https://doi.org/10.1016/j.molstruc.2022.132712
Baltgalvis, K. Lamb, K., Symons, K., Wu, C., Hoffman, M., Snead, A., & Kinsella, T. M. (2024). Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature, 629(8011), 435-442.
Bao, J., Liu, D., Sun, J., Su, X., Cheng, H., Qi, L. & Li, L. (2022). Pancreatic cancer-associated diabetes mellitus is characterized byreduced β-cell secretory capacity, rather than insulin resistance. Diabetes Research and Clinical Practice, 185, 109223. https://doi.org/10.1016/j.diabres.2022.109223
Chun, S., & Yee, N. S. (2010). Werner syndrome as a hereditary risk factor for exocrine pancreatic cancer: potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy. Cancer biology & therapy, 10(5), 430-437. https://doi.org/10.4161/cbt.10.5.12763
Clark, A., & Labute, P. (2007). 2D depiction of protein-ligand complexes. Journal of chemical information and modeling, 47(5), 1933-1944. https://doi.org/10.1021/ci7001473
Clauss, A., & Nelsen, S. (2009). Integrating computational molecular modeling into the undergraduate organic chemistry curriculum. Journal of chemical Education, 86(8), 955. https://doi.org/10.1021/ed086p955
Damian, L. (2013). Isothermal titration calorimetry for studying protein-ligand interactions. Protein-Ligand Interactions: Methods and Applications, 103-118.
Davis, T., Wyllie, F., Rokicki, M., Bagley, M., & Kipling, D. (2007). The role of cellular senescence in Werner syndrome: toward therapeutic intervention in human premature aging. Annals of the New York Academy of Sciences, 1100(1), 455-469.
Ding, S., Yu, J., Chen, S., Hsu, G., & Shen, C. Y. (2007). Genetic variation in the premature aging gene WRN: a case-control study on breast cancer susceptibility. Cancer Epidemiology Biomarkers & Prevention, 16(2), 263-269. https://doi.org/10.1158/1055-9965.EPI-06-0678
Einstein, A., Henzlova, M., & Rajagopalan, S. (2007). Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. Jama, 298(3), 317-323. https://doi.org/10.1001/jama.298.3.317
Ferretti, S., Hamon, J., De-Kanter, R., Scheufler, C., Andraos-Rey, R., Barbe, S., & Cortés-Cros, M. (2024). Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers, Nature, 629(8011), 443-449.
Figueroa-Valverde, L., Rosas-Nexticapa, M.., Alvarez-Ramirez, M., Lopez-Ramos, M., Mateu-Armand, V., & Patricia, H. V. (2024). Interaction of thiophene and their derivatives with BRCA-1 using a theoretical model. Clinical Cancer Investigation Journal, 13(2-2024), 40-44. https://doi.org/10.51847/4AnibsrLIW
Garcia-Pelaez, J., Barbosa-Matos, R., São José, C., Sousa, S., Gullo, I., Hoogerbrugge, N., & Oliveira, C. (2022). Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes. European Journal of Medical Genetics, 65(1), 104401.https://doi.org/10.1016/j.ejmg.2021.104401
Goto, M., Miller, R. W., Ishikawa, Y., & Sugano, H. (1996). Excess of rare cancers in Werner syndrome (adult progeria). Cancer epidemiology, biomarkers & prevention, 5(4), 239-246.
Hsu, T., Hsu, L., Chen, S., & Juang, B. (2021). MUT-7 Provides Molecular Insight into the Werner Syndrome Exonuclease. Cells, 10(12), 3457. https://doi.org/10.3390/cells10123457
Huang, S., Lee, L., Hanson, N. B., Lenaerts, C., Hoehn, H., Poot, M., & Oshima, J. (2006). The spectrum of WRN mutations in Werner syndrome patients. Human mutation, 27(6), 558-567. https://doi.org/10.1002/humu.20337
Huang, S., Li, B., Gray, M. D., Oshima, J., Mian, I. S., & Campisi, J. (1998). The premature ageing syndrome protein, WRN, is a 3′→ 5′ exonuclease. Nature genetics, 20(2), 114-116.
Jiang, Y., Meyers, T., Emeka, A., Cooley, L., Cooper, P., Lancki, N., & Witte, J. S. (2022). Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 3(1), 100070.https://doi.org/10.1016/j.xhgg.2021.100070
Jung, J., Lee, Y., Min, D., Jung, M., & Oh, S. (2017). Practical synthesis of chalcone derivatives and their biological activities. Molecules, 22(11), 1872. https://doi.org/10.3390/molecules22111872
Kim, J., Harper, A., McCormack, V., Sung, H., Houssami, N., Morgan, E., & Fidler-Benaoudia, M. (2025). Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nature Medicine, 1-9.
Kurczab, R., Śliwa, P., Rataj, K., Kafel, R., & Bojarski, A. (2018). Salt bridge in ligand–protein complexes-systematic theoretical and statistical investigations. Journal of Chemical Information and Modeling, 58(11), 2224-2238. https://doi.org/10.1021/acs.jcim.8b00266
Lazarus, E., & Bays, H. E. (2022). Cancer and obesity: an obesitymedicine association (OMA) clinical practice statement (CPS) 2022. Obesity Pillars, 3, 100026. https://doi.org/10.1016/j.obpill.2022.100026
Laxmi, K. (2017). Chemsketch study of phenobarbital: An antiepileptic drug. International Journal of Computational and Theorical Chemistry, 5(3), 25. doi: 10.11648/j.ijctc.20170503.11
Liu, R., Perez-Aguilar, J., Liang, D., & Saven, J. (2012). Binding site and affinity prediction of general anesthetics to protein targets using docking. Anesthesia & Analgesia, 114(5), 947-955. https://doi.org/ 10.1213/ANE.0b013e31824c4def
Murano, S., Mon. S., Morisaki, N., Yoshida, S., Matsuda, S., Furumoto, H., and Saito, Y. A case of Werner’s syndrome with death from primary brain tumor. Jpn. J. Gerontol., 31: 723, 1994.
Mayén, A., Viallon, V., Botteri, E., Proust-Lima, C., Bagnardi, V., Batista, V., & Ferrari, P. (2022). A longitudinal evaluation of alcohol intake throughout adulthood and colorectal cancer risk. European Journal of Epidemiology, 37(9), 915-929.https://doi.org/10.1007/s10654-022-00900-6
Minihan, A., Patel, A., Flanders, W., Sauer, A., Jemal, A., & Islami, F. (2022). Proportion of Cancer Cases Attributable to Physical Inactivity by US State, 2013-2016. Medicine and Science in Sports and Exercise, 54(3), 417-423.https://doi.org/10.1249/mss.0000000000002801
Mori, T., Nagai, K., Nakamura, H., Abe, K., Kimura, H., Saito, K., Kishikawa, T., Ishibashi, M., and Funie, H. (1993). A case of Werner’s syndrome with early gastric cancer treated with endoscopic mucosal resection. Progess of Digestive Endoscopy, 43, 170-174. http://dx.doi.org/10.11641/pdensks.43.0_170
Moon, B., Go, A., Park, S., Kim, H. J., An, D., Kim, J., & Kim, J. A. (2025). Discovery of novel WRN inhibitors for treating MSI-H colorectal cancers. Bioorganic & Medicinal Chemistry Letters, 130141. https://doi.org/10.1016/j.bmcl.2025.130141
Opresko, P., Laine, J., Brosh, R., Seidman, M., & Bohr, V. (2001). Coordinate action of the helicase and 3′ to 5′ exonuclease of Werner syndrome protein. Journal of Biological Chemistry, 276(48), 44677-44687.
Oshima, J. (2003), Werner syndrome. Chromosomal Instability and Aging, 185-204.
Rasul, H., Aziz, B., Ghafour, D., & Kivrak, A. (2022). In silico molecular docking and dynamic simulation of eugenol compounds against breast cancer. Journal of molecular modeling, 28(1), 17.
Reddy, G., Garcia, J., Reddy, V., De-Andrade, A., Camilo, A., Ribeiro, R., & De-Lazaro, S. (2016). Synthesis, antimicrobial activity and advances in structure-activity relationships (SARs) of novel tri-substituted thiazole derivatives. European journal of medicinal chemistry, 123, 508-513. http://dx.doi.org/10.1016/j.ejmech.2016.07.062
Roche, O., Kiyama, R., & Brooks, C. (2001). Ligand-protein database: Linking protein-ligand complex structures to binding data. Journal of medicinal chemistry, 44(22), 3592-3598. https://pubs.acs.org/cms/10.1021/jmcmar.2001.44.issue-22/asset/17b36692-3f17-3669-13f1-b3669213f17b/largecover.jpg
Sathishkumar, K., Chaturvedi, M., Das, P., Stephen, S., & Mathur, P. (2022). Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian journal of medical research, 156(4-5), 598-607.
Shamanna, R., Lu, H., Croteau, D., Arora, A., Agarwal, D., Ball, G., & Bohr, V. A. (2016). Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. Oncotarget, 7(12), 13269. https://doi.org/10.18632/oncotarget.7906
Suvorov, V., Igitov, V., & Lazarev, A. (2015). Effect of tobacco smocking on the risk of colorectal cancer development. Russian Journal of Oncology, 20(4), 46-48. https://doi.org/10.17816/onco40263
Tsuge, K., & Shimamoto, A. (2022). Research on werner syndrome: Trends from past to present and future prospects. Genes, 13(10), 1802. https://doi.org/10.3390/genes13101802
Verkhivker, G., Bouzida, D., Gehlhaar, D., Rejto, P., Arthurs, S., Colson, A., & Rose, P. W. (2000). Deciphering common failures in molecular docking of ligand-protein complexes. Journal of computer-aided molecular design, 14, 731-751.
Wang, Z., Xu, Y., Tang, J., Ma, H., Qin, J., Lu, C., & Shen, H. (2009). A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women. Breast cancer research and treatment, 118, 169-175.
Xiong, X., Zheng, L., Ding, Y., Chen, Y., Cai, Y., Wang, L, & Yu, K. (2025). Breast cancer: pathogenesis and treatments. Signal Transduction and Targeted Therapy, 10(1), 49.
Zabransky, D., Jaffee, E., & Weeraratna, A. (2022). Shared genetic and epigenetic changes link aging and cancer. Trends in cell biology, 32(4), 338-350. https://doi.org/10.1016/j.tcb.2022.01.004
Zhao, H., Dong, J., Lafleur, K., Nevado, C., & Caflisch, A. (2012). Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics. ACS medicinal chemistry letters, 3(10), 834-838. https://doi.org/10.1021/ml3001984
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Marcela Rosas Nexticapa, Magdalena Alvarez-Ramirez, Maria Virginia Mateu-Armad, Enrique Bonilla-Zavaleta, Regina Cauich-Carrillo, Lauro Figueroa-Valverde
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
